| Topic | Scale | k | Pooled | 95% CI | 95% PI | I² | Q p-val | τ² | HKSJ floor |
|---|---|---|---|---|---|---|---|---|---|
| AGYW_HIV_PREP | HR | 2 | withheld | withheld | withheld | 80.2% | 0.024 | 0.1703 | — |
The endpoint this number measures is not recorded anywhere we hold, so a value above 1 cannot be read as benefit or as harm. The trials have endpoints; we did not record them. This is our recording gap, not a property of the evidence. -- outputs/r_validation/AGYW_HIV_PREP.json | |||||||||
| ALIROCUMAB_LIPID_AUTO_FULL | OR | 3 | 0.125 | 0.000 to 52125070538259591374646059991040.000 | 0.000 to 19668586982865578720149804473547685789649154539597751520229064704.000 | 93.6% | 1.53e-07 | 912.6020 | Yes |
| ANIFROLUMAB_SLE | OR | 2 | 2.055 | 1.522 to 2.774 | 1.522 to 2.774 | 0.0% | 0.878 | 0.0000 | Yes |
| ANIFROLUMAB_SLE_AUTO_FULL | OR | 2 | 0.185 | 0.000 to 295.628 | — | 34.3% | 0.217 | 0.0000 | — |
| ANIFROLUMAB_SLE_REVIEW | OR | 2 | 1.750 | 0.263 to 11.656 | — | 0.0% | 0.403 | 0.0000 | Yes |
| ANTIFUNGAL_NEWER_RESISTANT | OR | 7 | 2.802 | 1.887 to 4.161 | 1.144 to 6.866 | 56.5% | 0.031 | 0.1080 | — |
| ANTIFUNGAL_NEWER_RESISTANT_REVIEW | RR | 5 | 1.307 | 0.335 to 5.103 | 0.047 to 36.385 | 51.5% | 0.083 | 1.1949 | Yes |
| AZILSARTAN_HTN_AUTO_FULL | OR | 4 | 0.966 | 0.735 to 1.270 | 0.735 to 1.270 | 0.0% | 0.540 | 0.0000 | Yes |
| AZILSARTAN_HTN_AUTO_FULL_REVIEW | MD | 4 | -4.990 | -6.822 to -3.158 | -6.822 to -3.158 | 0.2% | 0.391 | 0.0000 | — |
| BEMPEDOIC_ACID | OR | 4 | withheld | withheld | withheld | 64.7% | 0.028 | 0.0721 | — |
The store refused to pool this and recorded why: Nothing is pooled: one trial. This is not a withheld estimate -- the value stands and is CLEAR Outcomes' own.-- ssot/bempedoic-acid-review/bempedoic-acid-review.json | |||||||||
| BEMPEDOIC_ACID_REVIEW | MD | 4 | withheld | withheld | withheld | 82.6% | 3.00e-04 | 3.1677 | — |
The store refused to pool this and recorded why: Nothing is pooled: one trial. This is not a withheld estimate -- the value stands and is CLEAR Outcomes' own.-- ssot/bempedoic-acid-review/bempedoic-acid-review.json | |||||||||
| BPAL_MDRTB | OR | 3 | 2.961 | 0.454 to 19.304 | 0.090 to 97.351 | 84.4% | 0.003 | 0.4691 | — |
| BPAL_MDRTB_REVIEW | RR | 3 | 1.293 | 0.003 to 564.702 | 0.000 to 245752.204 | 88.0% | 2.40e-04 | 5.9844 | Yes |
| CAB_PREP_HIV | HR | 1 | withheld | withheld | withheld | 0.0% | 1.000 | 0.0000 | — |
The endpoint this number measures is not recorded anywhere we hold, so a value above 1 cannot be read as benefit or as harm. The trials have endpoints; we did not record them. This is our recording gap, not a property of the evidence. -- outputs/r_validation/CAB_PREP_HIV.json | |||||||||
| CANGRELOR_PCI | OR | 3 | withheld | withheld | withheld | 68.4% | 0.036 | 0.0176 | — |
The store refused to pool this and recorded why: THE NUMERATORS AND THE DENOMINATORS ON THIS PAGE COME FROM DIFFERENT OUTCOMES, ON ALL THREE TRIALS. Each row carried the primary composite's participant denominators -- 3,889 and 3,865; 2,654 and 2,641; 5,470 and 5,469, all exactly right -- against event counts of 8 and 5, 6 and 18, and 18 and 18. Those counts are NOT the composite's. They are ALL-CAUSE MORTALITY, a SECONDARY outcome on every one of the three: CHAMPION-PCI's 'Individual Incidence of All-cause Mortality' is 8 against 5, CHAMPION-PLATFORM's 'Incidence of All-cause Mortality' is 6 against 18, and CHAMPION-PHOENIX's 18 against 18 is the DEATH row of its stent-thrombosis/death/MI breakdown. THE REGISTRY'S OWN PRIMARY-COMPOSITE COUNTS ARE 290 AND 276, 185 AND 210, AND 257 AND 322 -- between one and two ORDERS OF MAGNITUDE larger than what the page used. A mortality numerator over a composite denominator is not a small error in a rate; it is a quantity that corresponds to nothing. AND THE CORRECTION REVERSES THE CONCLUSION, WHICH IS WHY THIS MATTERS MORE THAN A TIDINESS COMPLAINT. Pooling the registry's own primary counts by DerSimonian-Laird gives OR 0.8955 (0.7526 to 1.0656), I-squared 64 per cent -- AN INTERVAL THAT CROSSES NO EFFECT. The card published OR 0.81 (0.71 to 0.91), which EXCLUDES it. The page reported a significant benefit where the trials' own primary outcomes do not establish one. SEPARATELY AND SUFFICIENT ON ITS OWN: THE COMPOSITES ARE NOT THE SAME. CHAMPION-PHOENIX's registered primary is 'The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) AND STENT THROMBOSIS (ST)' -- four components. CHAMPION-PCI's and CHAMPION-PLATFORM's are mortality, MI and IDR: three. One whole component is present in one trial and absent from the other two, so even with correct counts these three would not share one estimand.-- ssot/cangrelor-pci-review/cangrelor-pci-review.json | |||||||||
| CANGRELOR_PCI_REVIEW | OR | 3 | withheld | withheld | withheld | 66.0% | 0.053 | 1.2907 | Yes |
The store refused to pool this and recorded why: THE NUMERATORS AND THE DENOMINATORS ON THIS PAGE COME FROM DIFFERENT OUTCOMES, ON ALL THREE TRIALS. Each row carried the primary composite's participant denominators -- 3,889 and 3,865; 2,654 and 2,641; 5,470 and 5,469, all exactly right -- against event counts of 8 and 5, 6 and 18, and 18 and 18. Those counts are NOT the composite's. They are ALL-CAUSE MORTALITY, a SECONDARY outcome on every one of the three: CHAMPION-PCI's 'Individual Incidence of All-cause Mortality' is 8 against 5, CHAMPION-PLATFORM's 'Incidence of All-cause Mortality' is 6 against 18, and CHAMPION-PHOENIX's 18 against 18 is the DEATH row of its stent-thrombosis/death/MI breakdown. THE REGISTRY'S OWN PRIMARY-COMPOSITE COUNTS ARE 290 AND 276, 185 AND 210, AND 257 AND 322 -- between one and two ORDERS OF MAGNITUDE larger than what the page used. A mortality numerator over a composite denominator is not a small error in a rate; it is a quantity that corresponds to nothing. AND THE CORRECTION REVERSES THE CONCLUSION, WHICH IS WHY THIS MATTERS MORE THAN A TIDINESS COMPLAINT. Pooling the registry's own primary counts by DerSimonian-Laird gives OR 0.8955 (0.7526 to 1.0656), I-squared 64 per cent -- AN INTERVAL THAT CROSSES NO EFFECT. The card published OR 0.81 (0.71 to 0.91), which EXCLUDES it. The page reported a significant benefit where the trials' own primary outcomes do not establish one. SEPARATELY AND SUFFICIENT ON ITS OWN: THE COMPOSITES ARE NOT THE SAME. CHAMPION-PHOENIX's registered primary is 'The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) AND STENT THROMBOSIS (ST)' -- four components. CHAMPION-PCI's and CHAMPION-PLATFORM's are mortality, MI and IDR: three. One whole component is present in one trial and absent from the other two, so even with correct counts these three would not share one estimand.-- ssot/cangrelor-pci-review/cangrelor-pci-review.json | |||||||||
| CAPMATINIB_LUNG_AUTO_FULL | OR | 2 | 4.361 | 0.002 to 12569.440 | — | 0.0% | 0.525 | 0.0000 | Yes |
| CEFTAROLINE_AUTO_FULL | OR | 4 | 0.335 | 0.000 to 7730527589570811904.000 | 0.000 to 6622004999592200427551464097219452262678528.000 | 97.9% | 3.72e-30 | 785.0380 | Yes |
| CEFTAROLINE_AUTO_FULL_REVIEW | RD | 3 | 7.211 | -1.381 to 15.802 | -1.381 to 15.802 | 0.0% | 0.677 | 0.0000 | Yes |
| CIPROFLOXACIN_UTI_AUTO_FULL | OR | 2 | 1.067 | 0.080 to 14.224 | — | 59.1% | 0.118 | 0.0000 | — |
| DELGOCITINIB_AD_AUTO_FULL | OR | 4 | 3.100 | 0.067 to 144.247 | 0.001 to 15267.239 | 66.2% | 0.031 | 5.6810 | Yes |
| DELGOCITINIB_AD_AUTO_FULL_REVIEW | RD | 3 | 15.109 | -82.894 to 113.112 | -179.888 to 210.106 | 73.6% | 0.023 | 1535.1248 | Yes |
| DELGOCITINIB_HAND_AUTO_FULL | OR | 4 | 3.100 | 0.067 to 144.247 | 0.001 to 15267.239 | 66.2% | 0.031 | 5.6810 | Yes |
| DELGOCITINIB_HAND_AUTO_FULL_REVIEW | RD | 3 | 15.109 | -82.894 to 113.112 | -179.888 to 210.106 | 73.6% | 0.023 | 1535.1248 | Yes |
| ELVITEGRAVIR_HIV_AUTO_FULL | OR | 4 | 1.001 | 0.632 to 1.585 | 0.632 to 1.585 | 0.0% | 0.980 | 0.0000 | Yes |
| ENDOMETRIOSIS_NEW_GNRH_NMA_REVIEW | RR | 6 | 2.369 | 0.123 to 45.522 | 0.001 to 5859.680 | 78.6% | 2.82e-04 | 7.9166 | Yes |
| EPILEPSY_NEW_AEDS | OR | 10 | 2.752 | 1.847 to 4.102 | 0.800 to 9.466 | 87.5% | 7.77e-11 | 0.2671 | — |
| EPILEPSY_NEW_AEDS_REVIEW | RR | 9 | 1.854 | 0.350 to 9.813 | 0.010 to 356.076 | 72.7% | 2.86e-04 | 4.6766 | Yes |
| EPILEPSY_NEW_AGENTS_NMA_REVIEW | RR | 8 | 2.688 | 0.324 to 22.300 | 0.005 to 1487.294 | 54.5% | 0.032 | 6.3340 | Yes |
| FRAGILITY_FRACTURE | OR | 4 | 0.329 | 0.184 to 0.589 | 0.107 to 1.014 | 74.4% | 0.008 | 0.0914 | — |
| FRAGILITY_FRACTURE_REVIEW | RR | 4 | 0.308 | 0.001 to 81.337 | 0.000 to 78116.651 | 76.5% | 0.005 | 12.2174 | Yes |
| GRANISETRON_CINV_AUTO_FULL | OR | 2 | 2.556 | 0.000 to 2217662959311.253 | — | 76.4% | 0.040 | 9.3191 | Yes |
| GnRH_ANTAGONISTS_GYN | OR | 9 | 10.881 | 6.534 to 18.122 | 2.552 to 46.386 | 83.2% | 2.36e-06 | 0.3464 | — |
| HFpEF_DRUGS_NMA | OR | 10 | 0.951 | 0.649 to 1.394 | 0.288 to 3.142 | 96.4% | 5.55e-14 | 0.2507 | — |
| HFpEF_DRUGS_NMA_REVIEW | HR | 7 | 0.832 | 0.774 to 0.895 | 0.774 to 0.895 | 0.0% | 0.720 | 0.0000 | Yes |
| HIP_FX_DISPLACED_NMA | OR | 10 | 0.682 | 0.615 to 0.757 | 0.615 to 0.757 | 0.0% | 0.887 | 0.0000 | Yes |
| HIV_ART_TIMING | OR | 3 | 0.467 | 0.062 to 3.525 | 0.010 to 22.377 | 93.7% | 1.32e-06 | 0.5880 | — |
| HIV_TB_COINFECTION_ART_TIMING | OR | 3 | 0.670 | 0.443 to 1.012 | 0.443 to 1.012 | 0.0% | 0.488 | 0.0000 | Yes |
| HIV_TB_COINFECTION_ART_TIMING_REVIEW | HR | 3 | 0.696 | 0.437 to 1.110 | 0.437 to 1.110 | 13.4% | 0.315 | 0.0000 | — |
| ICH_MIS_HEMATOMA_NMA_REVIEW | RR | 4 | 0.879 | 0.795 to 0.972 | 0.795 to 0.972 | 0.6% | 0.389 | 0.0000 | — |
| INCLISIRAN_LIPID_KIDNEY_AUTO_FULL | OR | 3 | 0.934 | 0.592 to 1.473 | 0.592 to 1.473 | 29.6% | 0.242 | 0.0000 | — |
| INCLISIRAN_LIPID_KIDNEY_AUTO_FULL_REVIEW | MD | 3 | -30.531 | -712.601 to 651.539 | -1393.797 to 1332.735 | 87.7% | 2.99e-04 | 75260.0372 | Yes |
| INCRETIN_HFpEF | OR | 3 | withheld | withheld | withheld | 9.4% | 0.194 | 0.0230 | — |
The store refused to pool this and recorded why: TWO OF THE THREE TRIALS ON THIS PAGE REGISTER ONLY CONTINUOUS PRIMARY OUTCOMES, AND THIS PAGE POOLED EVENT COUNTS. Verbatim: STEP-HFpEF and STEP-HFpEF DM each register two co-primaries, 'Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score' and 'Change in Body Weight'. Both are CONTINUOUS CHANGE SCORES. Neither is an event count and neither can produce a 2x2 table. The counts stored for STEP-HFpEF DM, 7 of 310 against 18 of 306, CORRESPOND TO NO REGISTERED PRIMARY OUTCOME OF THAT TRIAL. SUMMIT is different and is the only row here with a defensible source: it registers a continuous KCCQ primary AND 'First Occurrence of the Composite Endpoint of Heart Failure (HF) Outcomes', and its stored 29 of 364 against 52 of 367 do correspond to that event co-primary. So the pool joins one trial's registered event composite to another trial's unregistered counts. SEPARATELY: THE OUTCOME NAME AND THE MEASURE DESCRIBE DIFFERENT QUANTITIES. The outcome is named 'Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score' and the stored measure is an ODDS RATIO. A change score has no odds. SEPARATELY AGAIN, AND IT IS WHY THIS TOPIC WAS INVISIBLE: THIS PAGE'S CARD WAS INVISIBLE TO OUR OWN TOOLING. The card existed and published 'HR 0.41 (0.22 to 0.79), k=3' -- a measure, a value and a trial count that all differ from the object's OR 0.4846 (0.3178 to 0.7389) at k=2. It was reported as having NO CARD because two scripts matched card links with the pattern [A-Z0-9_]+\.html, which cannot match the lowercase 'p' in HFpEF. A page invisible to the tool that counts pages is worse than an uncounted one: it is counted as a different thing, and this card escaped card-alignment checking entirely for as long as those tools have run.-- ssot/incretin-hfpef-review/incretin-hfpef-review.json | |||||||||
| IPILIMUMAB_RENAL_AUTO_FULL | OR | 2 | 1.946 | 0.000 to 7722.851 | — | 0.0% | 0.860 | 0.0000 | Yes |
| IV_IRON_HF | OR | 4 | withheld | withheld | withheld | 82.6% | 3.10e-05 | 0.0743 | — |
This review's published estimate is RATE_RATIO 0.8066 (0.6856-0.9488) k=2. The odds ratio previously shown here was computed over a different trial set and is not a re-expression of it, so two surfaces were reporting different quantities with neither naming the other. The odds ratio is withheld rather than deleted: it is kept in the object as withheld_pool. -- withheld OR was OR 0.657 k=4 | |||||||||
| LEFAMULIN_CABP_AUTO_FULL | OR | 2 | 0.877 | 0.083 to 9.286 | — | 0.0% | 0.429 | 0.0000 | Yes |
| LIPID_HUB | OR | 5 | 0.887 | 0.717 to 1.098 | 0.569 to 1.383 | 76.7% | 9.27e-04 | 0.0196 | — |
| LORATADINE_RHIN_AUTO_FULL_REVIEW | MD | 3 | 0.053 | -0.668 to 0.774 | -0.668 to 0.774 | 96.5% | 3.75e-13 | 0.0000 | — |
| LUPUS_NEW_BIOLOGICS | OR | 10 | 2.118 | 1.694 to 2.647 | 1.356 to 3.308 | 36.0% | 0.086 | 0.0292 | — |
| LUPUS_NEW_BIOLOGICS_REVIEW | RR | 9 | 1.419 | 1.267 to 1.590 | 1.150 to 1.752 | 1.9% | 0.419 | 0.0059 | Yes |
| MDS_NEW_AGENTS | OR | 10 | 1.668 | 1.061 to 2.621 | 0.424 to 6.564 | 83.7% | 2.80e-09 | 0.3269 | — |
| MDS_NEW_AGENTS_REVIEW | RR | 6 | 1.645 | 0.015 to 178.123 | 0.000 to 392495.655 | 68.0% | 0.008 | 19.8832 | Yes |
| MELANOMA_NEOADJUVANT | OR | 3 | 0.844 | 0.006 to 120.138 | 0.000 to 6991.111 | 96.6% | 0.003 | 3.0687 | — |
| MELANOMA_NEOADJUVANT_REVIEW | HR | 2 | 0.431 | 0.000 to 1101479859868.364 | — | 78.5% | 0.031 | 10.0734 | Yes |
| NIRSEVIMAB_INFANT_RSV | OR | 3 | 0.224 | 0.146 to 0.345 | 0.146 to 0.345 | 0.0% | 0.721 | 0.0000 | Yes |
| OAB_BETA3_NMA | OR | 10 | 1.362 | 1.297 to 1.430 | 1.297 to 1.430 | 0.0% | 0.988 | 0.0000 | Yes |
| OAB_BETA3_NMA_REVIEW | RR | 5 | 1.174 | 1.073 to 1.284 | 1.073 to 1.284 | 0.0% | 0.928 | 0.0000 | Yes |
| OLANZAPINE_CINV_AUTO_FULL | OR | 3 | 1.141 | 0.000 to 2008971985834270.750 | 0.000 to 3475200751130110792177098424320.000 | 93.0% | 5.74e-07 | 199.5629 | Yes |
| OPIOID_INDUCED_CONSTIPATION | OR | 10 | 2.936 | 2.255 to 3.822 | 1.351 to 6.382 | 74.6% | 1.30e-05 | 0.1042 | — |
| PASIREOTIDE_CUSHING_AUTO_FULL | OR | 3 | 1.970 | 0.000 to 6647596215336365457408.000 | 0.000 to 21934592592009263577359440498672738286698496.000 | 90.8% | 1.96e-05 | 397.9552 | Yes |
| PBC_NEW_AGENTS | OR | 8 | 18.166 | 11.781 to 28.011 | 11.781 to 28.011 | 0.0% | 0.661 | 0.0000 | Yes |
| PBC_NEW_AGENTS_REVIEW | RR | 2 | 7.887 | 0.181 to 342.739 | — | 0.0% | 0.630 | 0.0000 | Yes |
| PRADER_HUMAN_GH_AUTO_FULL | OR | 2 | 1.212 | 0.003 to 580.169 | — | 56.2% | 0.131 | 0.0000 | — |
| PROPOSED_RHEUMATOID_ARTHRITIS_AUTO_FULL | OR | 4 | 0.934 | 0.662 to 1.319 | 0.662 to 1.319 | 0.0% | 0.882 | 0.0000 | Yes |
| PROSTATE_PARP_HRR_BROAD | OR | 7 | 0.532 | 0.373 to 0.758 | 0.221 to 1.279 | 78.4% | 2.48e-04 | 0.1076 | — |
| PROSTATE_PARP_HRR_BROAD_REVIEW | HR | 5 | 0.598 | 0.511 to 0.698 | 0.511 to 0.698 | 0.0% | 0.418 | 0.0000 | Yes |
| RNA_INTERFERENCE_BROAD_NMA_REVIEW | MD | 8 | -47.863 | -322.877 to 227.151 | -872.876 to 777.150 | 99.6% | 0.00e+00 | 108203.8001 | Yes |
| ROSUVASTATIN_AUTO_FULL_REVIEW | MD | 2 | -0.270 | -8.324 to 7.784 | — | 88.7% | 0.003 | 0.0000 | — |
| ROTAVIRUS_VACCINE_AFRICA | OR | 3 | 0.494 | 0.233 to 1.049 | 0.140 to 1.749 | 57.0% | 0.094 | 0.0557 | — |
| ROTAVIRUS_VACCINE_AFRICA_REVIEW | RR | 3 | 0.437 | 0.002 to 91.133 | 0.000 to 18474.404 | 66.2% | 0.052 | 4.5890 | Yes |
| ROXADUSTAT_ANEMIA_CKD_AUTO_FULL | OR | 2 | 0.768 | 0.000 to 342931606252968458914769529313689600.000 | — | 93.3% | 1.14e-04 | 83.4070 | Yes |
| ROXADUSTAT_ANEMIA_CKD_AUTO_FULL_REVIEW | MD | 2 | 0.239 | -2.420 to 2.897 | — | 93.0% | 1.59e-04 | 0.0000 | — |
| ROXADUSTAT_RENAL_ANEMIA_AUTO_FULL | OR | 2 | 0.768 | 0.000 to 342931606252968458914769529313689600.000 | — | 93.3% | 1.14e-04 | 83.4070 | Yes |
| ROXADUSTAT_RENAL_ANEMIA_AUTO_FULL_REVIEW | MD | 2 | 0.239 | -2.420 to 2.897 | — | 93.0% | 1.59e-04 | 0.0000 | — |
| SBRT_OLIGOMETS_NMA | OR | 10 | 0.536 | 0.393 to 0.730 | 0.275 to 1.042 | 31.5% | 0.216 | 0.0677 | — |
| SBRT_OLIGOMETS_NMA_REVIEW | HR | 2 | 0.479 | 0.043 to 5.284 | — | 0.0% | 0.521 | 0.0000 | Yes |
| SEPSIS_RESUSCITATION | OR | 3 | 0.957 | 0.737 to 1.244 | 0.737 to 1.244 | 0.0% | 0.572 | 0.0000 | Yes |
| SGLT2_BROAD_OUTCOMES_NMA | OR | 10 | 0.786 | 0.703 to 0.879 | 0.566 to 1.091 | 78.0% | 6.07e-06 | 0.0186 | — |
| SGLT2_BROAD_OUTCOMES_NMA_REVIEW | HR | 10 | 0.773 | 0.304 to 1.968 | 0.035 to 17.074 | 67.3% | 0.001 | 1.7014 | Yes |
| SGLT2_HF | OR | 5 | withheld | withheld | withheld | 79.2% | 0.005 | 0.0234 | — |
This review's published estimate is HR 0.7636 (0.7062-0.8258) k=3. The odds ratio previously shown here was computed over a different trial set and is not a re-expression of it, so two surfaces were reporting different quantities with neither naming the other. The odds ratio is withheld rather than deleted: it is kept in the object as withheld_pool. -- withheld OR was OR 0.709 k=5 | |||||||||
| SGLT2_MACE_CVOT | OR | 4 | 0.906 | 0.798 to 1.028 | 0.755 to 1.087 | 27.7% | 0.234 | 0.0017 | — |
| SGLT2_MACE_CVOT_REVIEW | HR | 4 | 0.909 | 0.822 to 1.005 | 0.822 to 1.005 | 0.0% | 0.499 | 0.0000 | Yes |
| SOTAGLIFLOZIN_HF | OR | 2 | withheld | withheld | withheld | 87.3% | 0.005 | 0.0628 | — |
This review's published estimate is HR 0.7171 (0.6246-0.8234) k=2. The odds ratio previously shown here was computed over a different trial set and is not a re-expression of it, so two surfaces were reporting different quantities with neither naming the other. The odds ratio is withheld rather than deleted: it is kept in the object as withheld_pool. -- withheld OR was OR 0.602 k=2 | |||||||||
| SOTAGLIFLOZIN_HF_REVIEW | HR | 2 | withheld | withheld | withheld | 0.0% | 0.512 | 0.0000 | Yes |
This review's published estimate is HR 0.7171 (0.6246-0.8234) k=2. The odds ratio previously shown here was computed over a different trial set and is not a re-expression of it, so two surfaces were reporting different quantities with neither naming the other. The odds ratio is withheld rather than deleted: it is kept in the object as withheld_pool. -- withheld OR was OR 0.602 k=2 | |||||||||
| STROKE_THROMBECTOMY_BROAD | OR | 11 | 2.650 | 2.010 to 3.493 | 1.239 to 5.664 | 55.9% | 0.008 | 0.1009 | — |
| STROKE_THROMBECTOMY_BROAD_REVIEW | RR | 10 | 2.039 | 0.291 to 14.299 | 0.003 to 1274.001 | 57.1% | 0.013 | 7.3564 | Yes |
| STROKE_THROMBECTOMY_LATE_NMA | OR | 10 | 2.694 | 2.160 to 3.360 | 1.872 to 3.875 | 18.6% | 0.229 | 0.0163 | — |
| STROKE_THROMBECTOMY_LATE_NMA_REVIEW | RR | 8 | 2.272 | 1.492 to 3.460 | 0.734 to 7.032 | 15.3% | 0.310 | 0.1966 | Yes |
| T1D_CLOSED_LOOP_NMA_REVIEW | MD | 3 | 10.704 | 7.289 to 14.119 | 7.289 to 14.119 | 0.0% | 0.753 | 0.0000 | Yes |
| TAVR_LOWRISK | OR | 3 | 0.630 | 0.381 to 1.043 | 0.381 to 1.043 | 0.0% | 0.491 | 0.0000 | Yes |
| TAVR_LOWRISK_REVIEW | HR | 3 | 0.644 | 0.368 to 1.126 | 0.368 to 1.126 | 0.0% | 0.457 | 0.0000 | Yes |
| TDXD_HER2LOW_BC | OR | 2 | 0.561 | 0.002 to 163.583 | 0.000 to 8285.956 | 93.0% | 1.51e-04 | 0.3713 | — |
| TROP2_ADC_BROAD | OR | 8 | 0.471 | 0.251 to 0.884 | 0.089 to 2.487 | 91.7% | 2.40e-05 | 0.4241 | — |
| TROP2_ADC_BROAD_REVIEW | HR | 3 | 0.603 | 0.000 to 5785.005 | 0.000 to 55134342.081 | 88.8% | 1.37e-04 | 13.6102 | Yes |
| UPADACITINIB_RA_AUTO_FULL | OR | 5 | 0.404 | 0.000 to 60646992.157 | 0.000 to 42856290068024958976.000 | 96.2% | 4.10e-22 | 229.8458 | Yes |
| VANCOMYCIN_CDI_AUTO_FULL | OR | 4 | 1.035 | 0.053 to 20.161 | 0.002 to 674.030 | 51.0% | 0.106 | 3.2738 | Yes |
| ZIRCONIUM_HYPERKALEMIA_AUTO_FULL | OR | 2 | 0.834 | 0.052 to 13.474 | — | 0.0% | 0.363 | 0.0000 | Yes |
| ZURANOLONE_PPD | OR | 2 | — | — | — | 0.0% | 0.416 | 0.0000 | Yes |
| ZURANOLONE_PPD_REVIEW | MD | 2 | -3.135 | -12.553 to 6.282 | — | 0.0% | 0.416 | 0.0000 | — |